NicOx S.A., a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glaucoma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., Inc. for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.

Show more

Employee Rating

2.0More
TypePublic
HQValbonne, FR
Size (employees)134 (est)
Websitenicox.com
NicOx is headquartered in Valbonne, FR
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at NicOx

Michele Garufi

Michele Garufi

Chairman and Chief Executive Officer, Chairman and Chief Executive Officer
Sandrine GESTIN

Sandrine GESTIN

Vice President, Finances
Tomas Navratil

Tomas Navratil

Executive Vice President, Head of Development
Emmanuelle Pierry

Emmanuelle Pierry

Senior Director of Legal Affairs
Gavin SPENCER

Gavin SPENCER

Executive Vice-President, Chief Business Officer
Michael BERGAMINI

Michael BERGAMINI

Chief Scientific Advisor
Show more

NicOx Office Locations

NicOx has offices in Valbonne, Fort Worth and Bresso
Bresso, IT
21 Via Ludovico Ariosto
Fort Worth, US
1292 777 Main St
Show all (3)
Report incorrect company information

NicOx News and Updates

Nicox teams up with Chinese firm to develop and sell glaucoma drug

French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive licence agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.

Dry Eye Syndrome Treatment Global Market 2018-2023: Novartis, Allergan, Otsuka, Nicox, Akorn

Wiseguyreports.Com Publish New Market Research Report On -“Dry Eye Syndrome Treatment Market - Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2018 - 2023” Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

NicOx Blogs

VYZULTA Approved in Canada by Nicox’s Partner

Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner has received approval in Canada of VYZULTATM (latanoprostene bunod ophthalmic solution), 0.024%. Bausch + Lomb, a leading global eye health company and whol…

Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq on Innovative Topical Ophthalmic Formulations

Encouraging preclinical efficacy data on NO-donating PDE5 inhibitors Focusing of research activities on the most promising new pharmacologic classes Collaboration with Novaliq to access novel formulation technology for these new compounds Sophia Antipolis, France Nicox SA (Euronext Paris: FR…

Nicox to present at the 30th Annual Piper Jaffray Healthcare conference

Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Michele Garufi, Chairman and Chief Executive Officer of Nicox, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday November 27, 2018 at 11:30…
Show more

NicOx Company Life and Culture

Report incorrect company information

NicOx Frequently Asked Questions

  • Who are NicOx key executives?

    NicOx's key executives are Michele Garufi, Sandrine GESTIN and Tomas Navratil.

  • How many employees does NicOx have?

    NicOx has 134 employees.

  • Who are NicOx competitors?

    Competitors of NicOx include Cesca Therapeutics, Celldex Therapeutics and Synthetic Biologics.

  • Where are NicOx offices?

    NicOx has offices in Valbonne, Fort Worth and Bresso.

  • How many offices does NicOx have?

    NicOx has 3 offices.